Enoblituzumab, previously known as TJ-271 or MGA271, represents the novel therapeutic specific to CD33, an antigen found predominantly on blood cells. This agent operates as the dual-action therapy, simultaneously https://lewisiszb793682.blognody.com/50554165/enoblituzumab-a-deep-dive-into-tj-271-and-mga271